Drug Trial Radar · NCT06669117
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Oct 21, 2030
Study completion Oct 1, 2032
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Conditions
- Solid Tumor
- MET Alteration
Interventions
VERT-002Drug
Route of Administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: All parts: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.Time frame: Screening to Safety Follow-up (30 days post last dose)
- Tolerability: All parts: Incidence of TEAEs/SAEs leading to VERT-002 dose reduction, interruption or discontinuation.Time frame: From screening up to 13 months
- Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From the start of trial treatment until end of Cycle 1 per dose level
- Part 1: Optimal Biologically Active Dose (OBD): Incidence on PK/PD and ORR (Objective Response Rate)Time frame: From the first VERT-002 intake up to 13 months
- Part2a: Preliminary activity assessment: ORR and cORR (Confirmed Objective Response Rate)Time frame: From the start of trial treatment up to 13 months
- Part2b: Recommended Phase 2 Dose (RP2D): Incidence on overall safety, PK, PDs and cORRTime frame: From the start of trial treatment up to 13 months
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Gabrail Cancer Research Center
Canton, Ohio · Recruiting
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
APHP de Marseille - Hôpital Nord
Marseille, France · Recruiting
Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
Saint-Herblain, France · Recruiting
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO)
Cologne, Germany · Recruiting
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Azienda Ospedaliero - Universitaria San Luigi Gonzaga
Orbassano, Italy · Recruiting
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands · Recruiting
Yonsei University College of Medicine
Seoul, South Korea · Recruiting
Asan Medical Center (AMC)
Seoul, South Korea · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Medical University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.